PT1633440E - Composição farmacêutica que compreende proteínas e/ou polipéptidos e partículas coloidais - Google Patents

Composição farmacêutica que compreende proteínas e/ou polipéptidos e partículas coloidais Download PDF

Info

Publication number
PT1633440E
PT1633440E PT04727664T PT04727664T PT1633440E PT 1633440 E PT1633440 E PT 1633440E PT 04727664 T PT04727664 T PT 04727664T PT 04727664 T PT04727664 T PT 04727664T PT 1633440 E PT1633440 E PT 1633440E
Authority
PT
Portugal
Prior art keywords
proteins
colloidal particles
polypeptides
polypeptide
protein
Prior art date
Application number
PT04727664T
Other languages
English (en)
Inventor
Moshe Baru
Lea Carmel-Goren
Original Assignee
Opperbas Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opperbas Holding Bv filed Critical Opperbas Holding Bv
Publication of PT1633440E publication Critical patent/PT1633440E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT04727664T 2003-04-15 2004-04-15 Composição farmacêutica que compreende proteínas e/ou polipéptidos e partículas coloidais PT1633440E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46270103P 2003-04-15 2003-04-15

Publications (1)

Publication Number Publication Date
PT1633440E true PT1633440E (pt) 2008-08-25

Family

ID=33299976

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04727664T PT1633440E (pt) 2003-04-15 2004-04-15 Composição farmacêutica que compreende proteínas e/ou polipéptidos e partículas coloidais

Country Status (15)

Country Link
US (1) US20070167359A1 (pt)
EP (1) EP1633440B1 (pt)
JP (1) JP2006523683A (pt)
CN (1) CN1774281B (pt)
AT (1) ATE395101T1 (pt)
AU (1) AU2004229253B2 (pt)
BR (1) BRPI0409424B8 (pt)
CA (1) CA2522179C (pt)
DE (1) DE602004013769D1 (pt)
DK (1) DK1633440T3 (pt)
ES (1) ES2307009T3 (pt)
MX (1) MXPA05010926A (pt)
PL (1) PL1633440T3 (pt)
PT (1) PT1633440E (pt)
WO (1) WO2004091723A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554161A1 (en) * 2011-08-02 2013-02-06 LFB Biotechnologies Pharmaceutical composition comprising factor VII encapsulated in micelles
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JPH0482839A (ja) * 1990-07-20 1992-03-16 Green Cross Corp:The 蛋白質類・脂質小体複合体
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
AU1916295A (en) * 1994-02-08 1995-08-29 Amgen, Inc. Oral delivery of chemically modified proteins
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
JP2001508783A (ja) * 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
PT1079805E (pt) * 1998-04-27 2005-03-31 Opperbas Holding Bv Composicao farmaceutica compreendendo factor viii e lipossomas neutros
CN1193059C (zh) * 1999-07-14 2005-03-16 阿尔萨公司 中性脂质聚合物以及含中性脂质聚合物的脂质体组合物
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
WO2002086117A1 (en) * 2001-04-20 2002-10-31 The University Of Vermont Compositions and methods to control bleeding
IL162319A0 (en) * 2001-12-04 2005-11-20 Univ Ben Gurion Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting

Also Published As

Publication number Publication date
AU2004229253A1 (en) 2004-10-28
EP1633440B1 (en) 2008-05-14
BRPI0409424B1 (pt) 2018-05-02
MXPA05010926A (es) 2005-11-25
CN1774281B (zh) 2010-10-13
AU2004229253B2 (en) 2009-11-05
ES2307009T3 (es) 2008-11-16
BRPI0409424A (pt) 2006-04-25
EP1633440A1 (en) 2006-03-15
DK1633440T3 (da) 2008-09-08
ATE395101T1 (de) 2008-05-15
BRPI0409424B8 (pt) 2021-05-25
DE602004013769D1 (de) 2008-06-26
US20070167359A1 (en) 2007-07-19
WO2004091723A1 (en) 2004-10-28
JP2006523683A (ja) 2006-10-19
CN1774281A (zh) 2006-05-17
CA2522179C (en) 2012-02-14
CA2522179A1 (en) 2004-10-28
PL1633440T3 (pl) 2008-12-31

Similar Documents

Publication Publication Date Title
EP2476697A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
EP1778842B8 (en) Compositions and methods of use for mgd-csf in disease treatment
MXPA00010241A (es) Composicion farmaceutica que comprende el factor viii y liposomas neutrales..
MY129566A (en) A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
CA2370289A1 (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
EP1845107A3 (en) RGD-enriched gelatine-like proteins with enhanced cell binding
DE60204714D1 (de) Pharmakologische nahrungszusammensetzung zur nahrungsergängzung und nährwertverbesserung
AUPP051497A0 (en) Antimicrobial peptides
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
EP1319023B8 (en) An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
EP0349342A3 (en) Polypeptides with cell-spreading activity
PT1633440E (pt) Composição farmacêutica que compreende proteínas e/ou polipéptidos e partículas coloidais
WO2001005810A3 (de) CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
CA2071757A1 (en) Implant compositions containing a biologically active protein, peptide or polypeptide
HK1046648A1 (en) Vaccines containing hybrid polypeptides consistingof at least two different allergenic proteins
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
EP1578772A4 (en) CYTOKINS AND CYTOKIN RECEPTORS WITH REDUCED IMMUNOGENICITY
EP1790655A3 (en) Biologically active peptides
WO2003002598A3 (en) Peptides for use as translocation factors
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
ATE452903T1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
WO2002083734A3 (en) Modified calcitonin
CA2163805A1 (en) Novel activating factor of leukocytes
EP2385124A3 (en) Peptides or peptide analogues for modulating the binding of a PDZ protein and a PL protein
WO2004032863A3 (en) Oral formulations for proteins and polypeptides